Determinants of eye drop size

Survey of Ophthalmology

Volumn 49, Issue 2, 2004, Pages 197-213

  Van Santvliet, Luc ^a   Ludwig, Annick ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Administration aids; Drop dispensing; Eye drop administration; Eye drop size; Ophthalmic solutions; Packaging

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; ECOTHIOPATE; EYE DROPS; SUXAMETHONIUM;

ASTHMA; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; DISPOSABLE EQUIPMENT; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG INDUSTRY; ECONOMIC ASPECT; HUMAN; INTRAOCULAR PRESSURE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY ARREST; REVIEW; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT WITHDRAWAL;

CHEMISTRY, PHARMACEUTICAL; DRUG PACKAGING; EQUIPMENT DESIGN; HUMANS; OPHTHALMIC SOLUTIONS;

EID: 1542301742     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2003.12.009     Document Type: Review

References (117)

1. Adler A., McElwain G., Merli G., Martin J. Systemic effects of eye drops. Arch Intern Med. 142:1982;2293-2294.
2. Armour D: Dropper plug. US Patent 2 987 223, 1961
3. Arnaud Y., Dauphin A., Mignot A. Interactions matières plastiques - medicaments. Postaire E. Les matières plastiques, à usage pharmaceutique et medico-chirurgical, tome I. 1986;121-172 Editions Médicales Internationales, Paris.
4. Ball S., Schneider E. Cost of beta-adrenergic receptor blocking agents for ocular hypertension. Arch Ophthalmol. 110:1992;654-657.
5. Barbeau D. Scientifically speaking. Addressing the therapeutic needs of the elderly. Control Rel Newsl. 14:1997;6-9.
6. Beebe D., Denton D., Radwin R., Webster J. A silicon-based tactile sensor for finger-mounted applications. IEEE Trans Biomed Eng. 45:1998;151-159.
7. Bendtsen L., Jensen R., Jensen N., Olesen J. Muscle palpation with controlled finger pressure: new equipment for the study of tender myofascial tissues. Pain. 59:1994;235-239.
8. Beyrich T. Notiz zur Beurteillung der Eindrückbarkeit von Plastikaugentropfenflaschen. Pharmazie. 31:1976;577.
9. Blaug S., Canada A. Relationship of viscosity, contact time and prolongation of action of methylcellulose containing ophthalmic solutions. Am J Hosp Pharm. 22:1965;662-666.
10. Bonnelye J, Chatelier J, Grégoire J: Embout goutte-à- goutte pour flacon, et flacon équipé d'un tel embout. Fr Patent 2 696 997, 1992
11. Bourny E., Dumolard L., Peronnet A. Remplissage intégré aseptique: la technologie blow-fill-seal (BFS) dans 'industrie pharmaceutique. STP Pharma Pratiques. 3:1995;203-214.
12. British Pharmaceutical Code 1973. 1973;The Pharmaceutical Press, London.
13. Brown J., Hotchkiss M., Davis B. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol. 99:1985;460-464.
14. Brown R., Lynch M. Design of eyedropper tips for topical beta-blocking agents. Am J Ophthalmol. 102:1986;123-124.
15. Bunin L: Bottle for controllably dispensing a liquid by drops. Eur Patent 0 362 911 A1, 1988
16. Burns E., Mulley G. Practical problems with eye drops among elderly ophthalmology outpatients. Age Ageing. 21:1992;168-170.
17. Busche S., Gramer E. Verbesserung der Augentropfenapplikation und Compliance bei Glaukompatienten. Klin Monatsbl Augenheilkd. 211:1997;257-262.
18. Carter S. Cooper and Gunn's Dispensing for Pharmaceutical Students. 1975;Pitman Medical, Kent, UK. pp 641-5.
19. Chau N., Pétry D., Bourgkard E., et al. Comparison between estimates of hand volume and hand strengths with sex and age with and without antropometric data in healthy working people. Eur J Epidemiol. 13:1997;309-316.
20. Chrai S., Makoid M., Eriksen S., Robinson J. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 63:1974;333-338.
21. Corlett A. Aids to compliance with medication. Br Med J. 313:1996;926-929.
22. Diamond J. Systemic adverse effects of topical ophthalmic agents. Implications for older patiens. Drugs Aging. 11:1997;352-360.
23. Diggory P., Franks W. Medical treatment of glaucoma - a reappraisal of the risks. Br J Ophthalmol. 80:1996;85-89.
24. Dispomed Ltd: Device for assisting dispensing. GB Patent 2 216 802 A, 1989
25. Dudinski O., Finnin B., Reed B. Acceptability of thickened eye drops to human subjects. Curr Ther Res. 33:1983;322-338.
26. European Pharmacopoeia. Strassburg, Council of Europe, 2002, ed 4
27. File R., Patton T. Topically applied pilocarpine, human pupillary response as a function of drop size. Arch Ophthalmol. 98:1980;112-115.
28. Fiscella R. Costs of glaucoma medications. Am J Health Syst Pharm. 55:1998;272-275.
29. Flach A. Systemic toxicity associated with topical ophthalmic medications. J Fla Med Assoc. 81:1994;256-260.
30. Frangie J. Clinical pharmacokinetics of various topical ophthalmic delivery systems. Clin Pharmacokinet. 29:1995;130-138.
31. Fraunfelder F., Meyer M. Systemic side effects from ophthalmic timolol and their prevention. J Ocul Pharmacol. 3:1987;177-184.
32. Fraunfelder F., Meyer S. Systemic adverse reactions to glaucoma medications. Int Ophthalmol Clin. 29:1989;143-146.
33. Glynn R., Seddon J., Krug J., et al. Falls in elderly patients with glaucoma. Arch Ophthalmol. 109:1991;205-210.
34. Heinlein H: Pipettiervorrichtung für Flaschen. Offenlegungsschrift 29 01 827, 1980
35. Holdsworth D., Roberts M., Polack A. Fate of chlorbutol during storage in polyethylene dropper containers and simulated patient use. J Clin Hosp Pharm. 9:1984;29-39.
36. Hook W., Stanley J. Assessment of thumb to index pulp to pulp pinch grip strengths. J Hand Surg. 11B:1986;91-92.
37. Hugues F., Le Jeune C. Systemic and local tolerability of ophthalmic drug formulations. Drug Saf. 8:1993;365-380.
38. Järvinen K., Järvinen T., Urtti A. Ocular absorption following topical delivery. Adv Drug Del Rev. 16:1995;3-19.
39. Jenkins W., Osborn K. Packaging drugs and pharmaceuticals. 1993;Technomic Publishing Co, Basel.
40. Jensen C: Eye drop alignment glasses. US Patent 5 255 024, 1993
41. Jensen T., Radwin R., Webster J. A conductive polymer sensor for measuring external finger forces. J Biomech. 24:1991;851-858.
42. Jho C., Burk R. Drop weight technique for the measurement of dynamic surface tension. J Colloid Sur Sci. 95:1983;61-71.
43. Jho C., Carreras M. The effect of viscosity on the drop weight technique for the measurement of dynamic surface tension. J Colloid Interface Sci. 99:1984;543-548.
44. Kass M., Gordon M., Meltzer D. Can ophthalmologists identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 101:1986;524-530.
45. Kass M., Meltzer D., Gordon M. A miniature compliance monitor for eyedrop medication. Arch Ophthalmol. 102:1984;1550-1554.
46. Koe M. Drop size of ocular timolol solutions. Am J Health Syst Pharm. 52:1995;2469.
47. Kooner K., Zimmerman T. A glaucoma time-table card. Ann Ophthalmol. 19:1986;43-44.
48. Lahdes K., Huupponen R., Kaila T., et al. Systemic absorption of ocular scopolamine in patients. J Ocul Pharmacol. 6:1990;61-66.
49. Lalueza Broto M., Montoro Ronsano J., Cano Marrón S., et al. Determinatión del tamaño de gota en colirios de timolol. Farm Clin. 6:1989;144-150.
50. Lang J. Ocular drug delivery conventional ocular formulations. Adv Drug Del Rev. 16:1995;39-43.
51. Lederer C., Harold R. Drop size of commercial glaucoma medications. Am J Ophthalmol. 101:1986;691-694.
52. Lee V. Precorneal, corneal, and postcorneal factors. Mitra A. Ophthalmic drug delivery systems. 1993;59-81 Marcel Dekker, Basel.
53. Lee V., Robinson J. Review: Topical ocular drug delivery, recent developments and future challenges. J Ocul Pharmacol. 2:1986;67-108.
54. Lee Y., Simomora P., Pinsuwan S., Yalkowsky H. Review on the systemic delivery of insulin via the ocular route. Int J Pharm. 233:2002;1-18.
55. Letocha C. Methods for self-administration of eyedrops. Ann Ophthalmol. 17:1985;768-769.
56. Loeffler M., Hornblass A. Hazards of unit dose artificial tear preparations. Arch Ophthalmol. 108:1990;639-640.
57. Loewenstein A., Bolocinic S., Goldstein M., Lazar M. Application of eye drops to the medial canthus. Graefe's Arch Clin Exp Ophthalmol. 232:1994;680-682.
58. Ludwig A., Van Ooteghem M. Influence of the surface tension of eye drops on the retention of a tracer in the precorneal area of human eyes. J Pharm Belg. 43:1988;157-162.
59. Lynch M., Brown R., Goode S., et al. Reduction of phenylephrine drop size in infants achieves equal dilatation with decreased systemic absorption. Arch Ophthalmol. 105:1987;1364-1365.
60. Marquardt N. Validation of Form-Fill-Seal. Pharm Ind. 57:1995;681-686.
61. Maruo S. The study of the pinching power. J Jpn Orthop Assn. 52:1979;979-988.
62. Mazuel C, Chalmin P: A dropper tip for dispensing a liquid, in particular eye drops. Eur. Patent 0 431 885 A1, 1989
63. McDonald F., Parkin J. The effect of disoidum edetate and sodium chloride on the stability of ethylmercury arising fro the decomposition of thimerosal (thiomersal). Drug Dev Ind Pharm. 21:1995;2403-2410.
64. Meier A., Hager H., Munzel K. Die dosierung von Flüssigkeiten mit Tropfgeräten. Pharm Acta Helv. 31:1956;177-254.
65. Mishima S., Gasset A., Klyce S., Baum J. Determination of tear volume and tear flow. Inv Ophthalmol. 5:1966;264-276.
66. Montoro J., Lalueza P., Cano S., et al. Drop size and systemic adverse effects in timolol ophthalmic solution. DICP Ann Pharmacother. 24:1990;439-440.
67. Morlet N., Kelly M. Improving drop administration by patients. J Ophthalmic Nurs Technol. 15:1996;60-64.
68. Morlet N., Morlet G. A method of drop administration. Ophthalmic Surg Lasers. 28:1997;687-689.
69. Morrow D., Leirer V., Sheikh J. Adherence and medication instructions. Review and recommendations. J Am Geriatr Soc. 36:1988;1147-1160.
70. Munroe W., Rindone J., Kershner R. Systemic side effects associated with the ophthalmic administration of timolol. Drug Intell Clin Pharm. 19:1985;85-89.
71. Nelson J. Corneal abrasion resulting from a unit dose artificial tear dispenser. Am J Ophthalmol. 103:1987;333-334.
72. Nordenskiöld U. Daily activities in women with rheumatoid arthritis. Scand J Rehabil Med. 37:(Suppl):1997;1-72.
73. O'Donoghue E. Beta blockers and the elderly with glaucoma: are we adding insult to injury? Br J Ophthalmol. 79:1995;794-796.
74. Olejnik O. Conventional systems in ophthalmic drug delivery. Mitra A. Ophthalmic Drug Delivery Systems. 1993;177-198 Marcel Dekker, Basel.
75. O'Sullivan E., Malhotra R., Migdal C. Prescription of eye drops. Postgrad Med J. 77:2001;654-655.
76. Palmer E. How safe are ocular drugs in pediatrics? Ophthalmology. 93:1986;1038-1040.
77. Partilla T., Skinner F., Dolder R. Behälter für flüssige Augenarzneien. Dolder R., Skinner F. Ophthalmica, Band I Pharmazeutische Grundlagen ihrer Zubereitung. 1990;576-591 Wissenschaftliche Verlagsgesellschaft, Stuttgart.
78. Patton F., Robinson R. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes. J Pharm Sci. 65:1976;1295-1301.
79. Patton T. Pharmacokinetic evidence for improved ophthalmic drug delivery by reduction of instilled volume. J Pharm Sci. 66:1977;1058-1059.
80. Patton T. Ocular drug disposition. Robinson J. Ophthalmic Drug Delivery Systems. 1980;27-53 American Pharmaceutical Association, Washington DC.
81. Petursson G., Cole R., Hanna C. Treatment of glaucoma using mini-drops of clonidine. Arch Ophthalmol. 102:1984;1180-1181.
82. Prince D., Carliner N. Respiratory arrest following first dose of timolol ophthalmic solution. Chest. 85:1983;640-641.
83. Quigley H. Number of people with glaucoma worldwide. Br J Ophthalmol. 80:1996;389-393.
84. Rivers P. Compliance aids - so they work? Drugs Aging. 2:1992;103-111.
85. Rosenthal A., Zimmerman J., Tanner J. Educating the glaucoma patient. Br J Ophthalmol. 67:1983;814-817.
86. Salminen L. Review: Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol. 6:1990;243-249.
87. Schwartz J., Christensen R., Lee D. Comparison of timolol maleate and levobunolol: doses and volume per bottle. Arch Ophthalmol. 107:1989;17-18.
88. Shaw D: Improvements in droppers for pharmaceutical liquids. GB Patent 1 169 255, 1969
89. Shell J. Ophthalmic drug delivery systems. Surv Ophthalmol. 29:1984;. 1779-28.
90. Shell J. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol. 26:1982;207-218.
91. Sinclair C., Tallentire A. Performance of Blow/Fill/Seal equipement under contolled airborne microbial challenges. PDA J Pharm Sci Techn. 49:1995;294-299.
92. Smith J. The need of ophthalmic patients for a compliance aid. Pharm J. 247:1992;721-722.
93. Smith S. Eyedrop instillation for reluctant children. Br J Ophthalmol. 75:1991;480-481.
94. Sorab J., Alle R., Gonik B. Tactile sensory monitoring of clinician-applied forces during delivery of newborns. IEEE Trans Biomed Eng. 35:1988;1090-1093.
95. Sorensen S., Abel S. Drop size of ocular carteolol hydrochloride. Am J Hosp Pharm. 51:1994;1470-1473.
96. Stevens J., Matheson M. Survey of the contamination of eyedrops of hospital inpatients and recommendatios for the changing of current practice in eyedrop dispensing. Br J Ophthalmol. 76:1992;36-38.
97. Stewart W., Sine C., Cate E., et al. Daily cost of β-adrenergic blocker therapy. Arch Ophthalmol. 115:1997;853-856.
98. United States Pharmacopeia. National Formulary. USP XXIV NF XIX. 1999;United States Pharmacopeial Convention Inc, Rockville, MD.
99. Urtti A., Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 37:1993;435-456.
100. Van Horssen N, Cox H. Verpakkingen, in Bolhuis G, Cox H, Zuidema J (eds): Receptuurkunde, Bereiden, keuren en afleveren van geneesmiddelen in de apotheek's Gravenhage, Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 1995, pp 152-205
101. Van Ooteghem M. Augenpräparate. Nürnberg E., Surmann P. Hagers Handbuch der pharmazeutischen Praxis Band 2 Methoden. 1991;633-637 Springer-Verlag, Berlin.
102. Van Ooteghem M., Ludwig A. Study on parameters influencing the drop volume of solutions from flexible dropper bottles. Abstract Proc 12th Pharm Techn Conf. 2:1993;612-622.
103. Van Santvliet L., Caljon K., Pieters L., Ludwig A. Physicochemical properties, NMR spectroscopy and tolerance of inclusion complexes of antazoline and tetracaine with hydroxypropyl-beta-cyclodextrin. Int J Pharm. 171:1998;147-156.
104. Van Santvliet L., Ludwig A. Influence of the dropper tip design on the size of eye-drops. Pharm Ind. 63:2001;402-409.
105. Van Santvliet L., Ludwig A. Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle. Eur J Pharm Sci. 7:1999;339-345.
106. Van Santvliet L., Ludwig A. Dispensing eye drops from flexible plastic dropper bottles Part I: Influence of the packaging characteristics. Pharm Ind. 61:1999;92-96.
107. Van Santvliet L., Ludwig A. Dispensing eye drops from flexible plastic dropper bottles Part II: Influence of the physico-chemical properties of the formulation and the manipulation technique by the patient. Pharm Ind. 61:1999;194-198.
108. Van Santvliet L., Ludwig A. Dispensing eye drops from flexible plastic dropper bottles Part III: Comparison between volunteers and healthy patients. Pharm Ind. 61:1999;276-280.
109. Van Santvliet L., Ludwig A. The influence of penetration enhancers on the volume instilled of eye drops. Eur J Pharm Biopharm. 45:1998;189-198.
110. Van Santvliet L., Sam T., Ludwig A. Packaging of ophthalmic solutions - Influence on stability, sterility, eye drop instillation and patient compliance. Eur J Pharm Biopharm. 42:1996;375-384.
111. Vocci M., Robin A., Wahl J., et al. Reformulation and drop size of apraclonidine hydrochloride. Am J Ophthalmol. 113:1992;154-160.
112. Webster J. Tactile sensors for robotics and medicine. 1988;Wiley, New York.
113. Weiss M., Hendrickson J. Information on drop size needs to be eyed closely. Am J Hosp Pharm. 51:1994;2969-2970.
114. Whitson J., Love R., Brown R., et al. The effect of reduced eyedrop size and eyelid closure on the therapeutic index of phenylephrine. Am J Ophthalmol. 115:1993;357-359.
115. Winfield A., Jessiman D., Williams A., Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 74:1990;477-480.
116. Wisher S. An assistive eye-drop mold. Am J Occup Ther. 45:1991;751-752.
117. Zimmerman T., Zalta A. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 28:1983;252-257.